Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
Want to see IN:CAPLIPOINT full AI Analyst Report?
CAPLIPOINT Stock Chart & Stats
₹1845.95
-₹76.70(-2.97%)
At close: 4:00 PM EST
₹1845.95
-₹76.70(-2.97%)
Day’s Range― - ―
52-Week Range₹1,502.45 - ₹2,396.95
Previous CloseN/A
Volume128.91K
Average Volume (3M)3.75K
Market Cap
₹153.26B
Enterprise Value₹147.83B
Total Cash (Recent Filing)₹10.17B
Total Debt (Recent Filing)₹85.00M
Price to Earnings (P/E)17.8
Beta1.24
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)77.45
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)3.19
Price to Sales (P/S)5.23
P/FCF Ratio33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.6
Revenue Forecast (FY)₹23.73B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin StrengthCaplin Point’s sustained revenue growth alongside mid‑50% gross margins and net margins in the 20s indicates durable product pricing power and efficient manufacturing. This fundamental margin profile supports multi-quarter cash generation, reinvestment into capacity, and resilience versus cyclical demand swings.
Conservative Balance SheetAn exceptionally conservative balance sheet with ultra‑low leverage materially reduces refinancing and solvency risk. Over a 2–6 month horizon this financial flexibility enables funding of capex or M&A without stress, preserves credit optionality, and cushions operational or regulatory setbacks.
Improving Cash GenerationOperating cash flow has meaningfully improved and free cash flow surged in the latest period, demonstrating stronger cash conversion. Persistent cash generation reduces reliance on external financing, supports strategic investments in high-complexity dosage forms, and underpins sustainable capital allocation over coming quarters.
Bears Say
Margin VolatilityRecent signs that gross profit growth lagged revenue point to margin compression possibly from cost pressure or pricing challenges for certain formulations. If this structural pressure persists, it can erode free cash flow and limit funding for capacity or R&D, pressuring multi‑quarter earnings sustainability.
Uneven Free Cash FlowThe pattern of volatile free cash flow, including a sharp FY2023 dip and FCF often well below net income, suggests working‑capital swings or lumpy investment timing. This unpredictability can complicate reliable dividend policy, buybacks, or planned reinvestments across the medium term.
ROE Moderation RiskReturns on equity have been robust, but the company’s equity base has expanded materially. If equity continues to grow faster than net income, ROE could decline, signaling weakening capital efficiency. Over several quarters this would constrain the firm’s ability to deliver comparable shareholder returns absent faster profit growth.
Caplin Point Laboratories Limited News
CAPLIPOINT FAQ
What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2396.95 in the past 12 months.
What is Caplin Point Laboratories Limited’s market cap?
Caplin Point Laboratories Limited’s market cap is ₹153.26B.
When is Caplin Point Laboratories Limited’s upcoming earnings report date?
Caplin Point Laboratories Limited’s upcoming earnings report date is Aug 12, 2026 which is in 82 days.
How were Caplin Point Laboratories Limited’s earnings last quarter?
Caplin Point Laboratories Limited released its earnings results on May 14, 2026. The company reported ₹22.4 earnings per share for the quarter, beating the consensus estimate of N/A by ₹22.4.
Is Caplin Point Laboratories Limited overvalued?
According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited pays a Quarterly dividend of ₹3 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here
What is Caplin Point Laboratories Limited’s EPS estimate?
Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caplin Point Laboratories Limited have?
Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
Caplin Point Laboratories Limited reported an EPS of ₹22.4 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 9.769%.
Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
Currently, no hedge funds are holding shares in IN:CAPLIPOINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
―
Granules India Limited
―
NATCO Pharma Limited
―
Neuland Laboratories Ltd.
―